In a regulatory filing, the company stated, “Biogen (BIIB) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the first quarter of 2026 by approximately $0.19 per share.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $237 from $228 at H.C. Wainwright
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Biogen price target raised to $275 from $250 at Oppenheimer
- Biogen price target raised to $245 from $230 at Canaccord
- Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio